TrialJournal of neurodevelopmental disorders2025

Long-term safety and tolerability of transdermal cannabidiol gel in children and adolescents with Fragile X syndrome (ZYN2-CL-017): an interim analysis of an ongoing open-label extension study.

Elizabeth Berry-Kravis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.